EXAMPLE THREE 
ARTEMIS Review â€” Weight Gain: Non-ARV Causes Identified
Weight gain is most likely from undertreated hypothyroidism and amitriptyline, not DTG
ğŸ” Most likely cause: Undertreated hypothyroidism (TSH 12.4) + amitriptyline side effect
The patient has been on DTG for 3 years but weight gain only accelerated in the past year â€” coinciding with starting amitriptyline (a drug known to cause significant weight gain) and diagnosis of hypothyroidism (which is currently undertreated: TSH 12.4, target <4.5). Clinical signs support hypothyroidism as the main driver: dry skin, periorbital oedema, delayed ankle reflex relaxation. DTG may be a minor contributor, but the reversible causes should be addressed first before considering any ARV change.

Suggested Management Plan
ğŸ”„ REVIEW
Clinician's plan: Considering switching from DTG due to weight gain
Consider instead: Do not switch ARV regimen at this time. Address the reversible causes first.
Reason: The weight gain coincides with amitriptyline and undertreated hypothyroidism, not with DTG initiation (patient was stable on DTG for 2 years before weight gain started). Switching ARVs now would not fix the weight gain and would add unnecessary complexity. Reassess weight trend after thyroid is optimised and amitriptyline is reviewed.
â• ADD
Not in current plan
Consider adding: Increase levothyroxine to 75â€“100 mcg daily. Emphasise daily adherence. Recheck TSH in 6 weeks.
Reason: TSH 12.4 is severely elevated â€” current dose of 50 mcg is insufficient. Patient admits poor adherence. Undertreated hypothyroidism alone explains the weight gain, fatigue, and dyslipidaemia.
â• ADD
Not in current plan
Consider adding: Discuss with mental health team about switching amitriptyline to a weight-neutral antidepressant (e.g. fluoxetine).
Reason: Amitriptyline (tricyclic antidepressant) causes significant weight gain. Fluoxetine (SSRI) is weight-neutral and has no significant interaction with TLD. The mental health team should make this decision given the depression diagnosis.
â• ADD
Not in current plan
Consider adding: Reassess weight trajectory in 3 months after thyroid optimised and antidepressant reviewed.
Reason: If weight stabilises or decreases after addressing these two causes, no ARV change needed. If weight continues to rise despite optimised thyroid and weight-neutral antidepressant, then reconsider DTG's contribution at that point.

Monitoring: TSH in 6 weeks (target <4.5). Weight at each visit. Fasting glucose and lipids in 3 months (expect improvement as thyroid normalises). Mood assessment at each visit.
Counselling: Explain that the weight gain appears to be mainly from the underactive thyroid and the depression medication, not the HIV medication. Taking the thyroid medication every day is very important â€” suggest linking it to a daily habit (e.g. before morning tea). A change in the depression medication may be discussed with the mental health team. Continue current HIV medication for now.
ğŸ“– Uganda Consolidated HIV Guidelines 2022: DTG-associated weight gain is acknowledged but should be a diagnosis of exclusion after addressing other reversible causes.